Outcome of ABO-Incompatible Living Donor Renal Transplantations: A Single-Center Experience From Eastern India  by Ray, D.S. & Thukral, S.
Outcome of ABO-Incompatible Living Donor Renal Transplantations:
A Single-Center Experience From Eastern India
D.S. Ray* and S. Thukral




Background. With the incessantly increasing number of patients on the waiting list for
renal transplants, crossing the blood group barrier can substantially increase the donor
pool. We started ABO-incompatible (ABOi) renal transplantation in 2013 with a relatively
low-cost preconditioning protocol (additional cost, w$1200). This study reports the short-
term outcome of ABOi renal transplantations performed at our institution.
Methods. A total of 45 adult ABOi kidney transplant recipients (KTRs) were included in
the study. All of them underwent a pretransplantation conditioning program, which
included plasmapheresis, low-dose intravenous immunoglobulin (IVIG), and low-dose
rituximab. A pretransplantation isoagglutinin titer of 1:8 was considered acceptable for
transplantation until December 2014, after which the threshold was increased to 1:32.
Results. Overall, 50% of KTRs were of blood group O. The maximum initial antibody
titer was 1:2048. All the patients achieved immediate graft function post-transplantation.
The mean serum creatinine level at 370 days (median duration of follow-up) was
1.21 mg%. One graft was lost due to severe antibody-mediated rejection (ABMR) with
cortical necrosis. The graft survival rate was 97.78% and the patient survival rate was
97.78%. The overall result in terms of graft and patient survival, infections, and
rejections were similar to ABO-compatible transplantations.
Conclusions. ABOi renal transplantation is a cost-effective modality to increase the
donor pool. Contrary to the belief that this modality is extremely expensive and requires
elaborate infrastructure, we had a good short-term outcome with a relatively simple and
low-cost preconditioning protocol.*Address correspondence to Dr. Deepak Shankar Ray,
Rabindranath Tagore International Institute of Cardiac Sciences,
124, EM Bypass, Mukundapur, Kolkata 700099, India. E-mail:
deepak_ray@hotmail.comASUCCESSFUL kidney transplantation provides alonger and better quality of life than dialysis to end-
stage renal disease (ESRD) patients [1]. The number of
candidates on the waiting list has nearly doubled since 2002
from w50,000 to more than 96,000 by 2013 [2].
Over the years, the eligibility criteria for living donor
programs have been expanded by the following: (1) ABO-
incompatible (ABOi) renal transplantation; (2) paired
donor exchange program; and (3) transplantation across a
positive cross-match. Solid organ transplantation has
traditionally been governed by the rules of blood group
compatibility. Immediate and, in most instances, irrepa-
rable graft losses have occurred due to an unintentional
breach of the ABO barrier [3e5]. Since the last 2 decades,6
.org/10.1016/j.transproceed.2016.06.048ABOi transplantation protocols have evolved to speciﬁc
isoagglutinin elimination techniques without the need for
splenectomy, reduction in isoagglitinin production, and
modulation of immune response. Various preconditioning
protocols differ with respect to isoagglutinin removal
techniques, accepted and target isoagglutinin titer, method
of isoagglutinin detection, and immunosuppression
maintenance.ª 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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ABO-INCOMPATIBLE LIVING DONOR RENAL TRANSPLANTS 2623ABOi renal transplantations are still uncommon in the
developing countries due to additional ﬁnancial burden and
lack of infrastructure. We started the ABOi living donor
program in April 2013 and introduced a relatively low-cost
preconditioning protocol at our institution. The aim of the
present study was to assess the short-term result of these
transplantations.Table 1. Demographic Data of Patients
No. of patients 45
Male:female 36:9
Recipient age (y)











Mean  SD 45  9.1
Range 23e60
Male:female ratio 8:37MATERIALS AND METHODS
The present study was a retrospective observational study, con-
ducted from April 2013 to April 2015 at Rabindranath International
Institute of Cardiac Sciences, Kolkata, India. The study was
approved by the Institutional Ethics committee (IEC). Written
informed consent was obtained from all the patients. All ABOi
kidney donor-recipient combinations were evaluated for ABOi
transplantation after routine pretransplantation screening.
Pretransplantation Conditioning Protocol
Antibody Depletion. Isoagglutinin removal was achieved by
repeated sessions of plasmapheresis, which was started on day 7.
The plasmapheresis sessions was determined by serial titration of
antibodies. Plasma exchange (PE) volume was 30 mL/kg body
weight and the replacement ﬂuid used was Ringers lactate and fresh
frozen plasma (FFP). FFP of the donor blood group was used.
Apheresis was done on alternate days till the target isoagglutinin
level was reached.
The accepted baseline antibody titer was 1:2048. A titer of 1:8
was considered acceptable for transplantation until December 2014,
after which a titer of 1:32 was accepted.
Immunomodulation. Rituximab (anti-CD 20, 200 mg) was
administered on day 15 and was diluted in 0.9% normal saline
(NS) over 1 hour after premedication with hydrocortisone.
Intravenous immunoglobulin (IVIG; 5 g) was administered after
each apheresis session. A total dose of 10e25 g was given. Induction
was given to all patients with anti-thymocyte globulin (ATG) at a
total dose of 3 mg/kg body weight in 2 divided doses on day 0 and
day 1 post-transplantation. Methyl prednisolone (MPRED) was
given in 2 doses of 500 mg on day -1 and day 0.
Immunosuppression Maintenance. Triple immunosuppres-
sion was maintained with tacrolimus (TAC; 0.15 mg/kg/d), myco-
phenolate mofetil (MMF; 1500 mg/d), and prednisolone (Pred;
20 mg/d), which was administered on day 15. The preconditioning
protocol is shown in Fig 1.
Isoagglutinin Measurement
The conventional tube method was used for periodic measurement
of antibody titers. Immunoglobulin G (IgG) and immunoglobulin M
(IgM) concentrations were measured separately. The recipient
serum was serially diluted and incubated with 1% reagent red blood
cells (RBCs; A/B) for 10 minutes at room temperature in the so-
dium chloride (NaCl) enzyme test columns. After the mixture was
centrifuged, macroscopic agglutination of RBCs was checked for
IgM detection. The last column to show 1þ reaction was considered
the end point. For IgG detection, additional testing with anti-
human globulin (AHG) columns was performed. Agglutination
was checked after incubation at 37C for 15 minutes. After 10 mi-
nutes, centrifugation was done. The last column to show 1þ reac-
tion was considered the end-point IgG titer. The assay time was
30e60 minutes. Titration was done at baseline, before eachsession of apheresis, IVIG administration, and immediately pre-
transplantation and post-transplantation.
This was done on a daily basis during the in-hospital stay. After
discharge, it was done 3 times a week for 30 days, every week for
2 months, every 15 days for 90 days, and monthly for 6 months. The
test was also repeated whenever there was an impairment of renal
function of the patients. No protocol biopsies were done in the
group; these were done only when indicated clinically.
Follow-Up
Triple immunosuppression was continued during the follow-up. The
target trough level of TAC was 10e12 ng/mL, and later reduced to
5e8 ng/mL at 3 months and 3e5 ng/mL at 6 months. After 6 months
post-transplantation, the MMF dose was reduced to 1 g/d. Post-
transplantation, Pred (50 mg/d) was given and tapered to 20 mg/
d by the end of 1 month. Tapering continued by 2.5 mg/month till a
maintenance dose of 7.5 mg/d was reached.
Anti-viral prophylaxis was given to all patients. Valgancyclovir
(450 mg/d) was administered for 90 days, regardless of cytomega-
lovirus (CMV) status. All the patients also received sulphame-
thoxazole (400 mg) or trimethoprim (80 mg) once a day for
6 months as prophylaxis against Pneumocystis jirovecii pneumonia.RESULTS
The study included 45 adult patients who had undergone
ABOi kidney transplantation (ABOiKT). All the patients
were complement dependent cytotoxicity (CDC) cross-
match negative.
The mean age of recipients and donors at the time of
transplantation was 43  12.5 years (range, 18e61 years)
and 45  9.16 years (range, 23e60 years), respectively.
Recipients comprised 36 males (80%) and 9 females (20%).
The donor group comprised 8 males (17.8%) and 37
females (82.2%). The relationship between donor and
recipient were parent and child for 28.8%, spousal for
62.2%, siblings for 4.4%, and unrelated for 4.4%. The
demographic data of all the patients is shown in Table 1.
The blood group distribution and blood group combinations
of patients are shown in Fig 2.
Fig 1. Blood group distribution and combinations of patients.
2624 RAY AND THUKRALThere were no pre-emptive transplantations and no
retransplantations. All the patients achieved immediate
graft function after transplantation and there was no
episode of acute rejection till discharge. No patient had
delayed graft function.
The initial isoagglutinin levels ranged from 1:8 to 1:2048.
Approximately 6 sessions of apheresis were required to
bring the titers to an acceptable level. The results of the
study are summarized in Table 2 and Table 3. The baseline
isoagglutinin titers are presented in Fig 3.
The median follow-up period was 370 days. The
patient survival rate was 97.8%. The death-censored graftFig 2. Preconditiosurvival rate was 97.8%. Excellent graft function was
observed at follow-up with a mean serum creatinine level
of 1.20  0.2 mg%.
One patient was readmitted after 30 days post-
transplantation with sepsis secondary to Burkholderia
cepacia pneumonitis. The patient developed acute antibody-
mediated rejection (ABMR) after withholding immuno-
suppression. Isoagglutinin titer of the patient was increased
to 1:16 and the patient developed anuric renal failure.
Renal biopsy showed Banff Grade 3 rejection. Rejection
was resistant to treatment with multiple sessions of apher-
esis, and IVIG. The renal allograft was lost within 45 daysning protocol.
Table 2. Preconditioning Details of ABOiKTRs
Apheresis Sessions (Pre-tpt) Anti IgG (Baseline) Anti IgG (Pre-tpt) IVIG Dose
Median (range) 4 (2e6) 1:64 (1:8e1: 2048) 1:4 (0e1:32) 15 g (10e25 g)
Abbreviations: KTRs, kidney transplant recipients; Pre-tpt, pretransplantation.
ABO-INCOMPATIBLE LIVING DONOR RENAL TRANSPLANTS 2625post-transplantation, although the patient is alive and is
presently maintained on hemodialysis.
One patient was readmitted after 4 months post-
transplantation with renal dysfunction and increased isoag-
glutinin titers. Renal biopsy showed acute pyelonephritis,
which improved with appropriate antibiotics. During the
course of the study, 1 patient with a functioning graft died
10 days post-transplantation. The patient developed sepsis
secondary to multi-drug resistant (MDR) Acinetobacter
infection.DISCUSSION
Because the life expectancy of patients who receive a
transplant is almost double that of those on dialysis, the
demand for kidney transplantation is constantly growing [6].
Kidneys from living donors have a predicted half-life twice
that of deceased donor organs, therefore, expansion of the
donor pool is essential [7]. Because ABO incompatibility
accounts for 30% of living donor exclusions, efforts have
been made to overcome this immunologic barrier.
The ﬁrst ABOi renal transplantation was reported by
Hume et al [3] in 1954, which was unsuccessful, followed by
3 successful ABOi renal transplantations [4]. There were
several unsuccessful attempts in the next 2 decades with low
graft survival rates [5]. Therefore, ABO incompatibility was
considered an absolute contraindication till Alexandre et al
reported the successful outcome of 26 ABOi trans-
plantations using splenectomy and plasmapheresis for pre-
conditioning [8]. In the 1980s and 1990s, splenectomy was
commonly performed for ABOi transplantations but overall
rejection rates were relatively high (29.3%e59%) in
recipients who underwent splenectomy [9e11].
With the introduction of the anti CD-20 antibody ritux-
imab, splenectomy is no longer required for successful
ABOi renal transplantations. Rituximab was ﬁrst used in theTable 3. Outcomes of ABOiKTRs
Outcomes
Patient survival rate (%) 97.78%
Graft survival rate (%) 97.78%
Acute cellular rejection Nil
Acute ABMR 2.22%
Serum creatinine at discharge (mg %) 1.21  0.52
Post-transplantation (median)
30 d 1.40  0.40
60 d 1.30  0.45
180 d 1.1  0.30
370 d 1.20  0.20
Postoperative duration of hospital stay (range) 10e15 d
Abbreviation: ABMR, antibody-mediated rejection.context of ABOi renal transplantation in combination with
double ﬁltration plasmapheresis (DFPP) and splenectomy
in 2002 [12]. The ﬁrst description of the use of rituximab in
place of splenectomy came from Stockholm in 2003 [13].
This strategy has now become widespread [9,14e28].
The overall outcomes of ABOi transplantations have
improved over the past 2 decades with better iso-
hemagglutinin removal techniques, potent immunosup-
pression, and immunomodulation. Most of the regimens use
an antibody removal technique such as therapeutic plas-
mapheresis, DFPP, or antigen-speciﬁc immunoadsorption
(IA) to bring the isoagglutinin level to an acceptable pre-
transplantation level, which varies between various centers.
In most centers, the acceptable target for isoagglutinin
titer is 1:8 on the day of transplantation [22,24,29,30,32].
In other studies the target acceptable isoagglutinin level for
transplantation is 1:16 [10,33,34]. At our center, the
acceptable isoagglutinin titers were 1:8 until December
2014, after which the threshold was increased to 1:32. No
episode of hyperacute rejection or ABMR was observed in
our patients.
In another study done by Toki et al, the maximum
acceptable titer was 1:16 until the year 2000, after which
the acceptable isoagglutinin titer was 1:32 [35,36]. Over
the past 20 years, several antibody-depleting strategies have
evolved. Therapeutic apheresis is the simplest and the
cheapest of all the strategies. Each session removes 20% of
anti-ABO antibodies. However, it has a disadvantage of
coagulation factors, hormones, and anti-viral and antibac-
terial IgG and IgM removal [37]. Some studies by Gloor
et al [9], van Agteren et al [38], and Squifﬂet et al [39] have
shown successful use of therapeutic plasma exchange (TPE)
along with rituximab for antibody depletion.
An average of 6 pretransplantation and 5 post-
transplantation apheresis sessions were required in 60
consecutive ABOiKTs [33]. Montgomery et al reported that
the number of sessions of TPE ranged from 2 for a titer of
1:16 to 10 for a titer of 1:512. An average of 2e5 post-
transplantation sessions was also required [10]. Lipshutz
et al [40] observed that the number of PE sessions depends
on initial isoagglutinin titers, ranging from 4e5 for a titer of
1:16 to 18 for a titer of 1:1024. The number of post-
transplantation sessions ranged from 0e12. A study con-
ducted in Japan has shown thatw3e4 sessions of DFPP are
required pretransplantation. No post-transplantation
apheresis was done unless there was an ABMR [30,35].
Antigen-speciﬁc IA has been successfully used at many
centers with good outcomes [22,24,34,38,41]. Morath et al
[34] used antigen-speciﬁc IA in the earlier and nonspeciﬁc IA
in the later phase of their study. About 4e6 IA treatments
with plasma volume of 85 mL/kg or 5e8 nonantigen speciﬁc
Fig 3. Baseline IgG titer distribution of patients.
2626 RAY AND THUKRALIA sessions with plasma volume of 106 mL/kg were used.
Post-transplantation apheresis sessions ranged from 1e8. A
patient with an initial IgG titer of 1:1024 could not undergo
transplantation even after 6 antigen-speciﬁc IA and 12 TPE
sessions because of strong antibody rebound. IA is expensive
and the cost of antigen-speciﬁc IA is w4500 Euros/session
and noneantigen-speciﬁc IA in antibody-depleting strategies
costs w1500 Euros. In a Swiss protocol wherein the post-
transplantation immunosorption was done if titers exceeded
1:8 in the ﬁrst week and 1:16 in the second week, 2e18 pre-
transplantation sessions with 2 volumes of PE and 0e11 post-
transplantation sessions with a single volume of exchange
were done. Antigen-speciﬁc IA was used by Tyden et al [13]
(4 sessions), and Donauer et al [32] (w7 sessions) for isoag-
glutinin depletion pretransplantation. The post-
transplantation protocol was similar to the Swiss protocol
[42].
We used therapeutic plasmapheresis for preconditioning
at our center. The plasma volume exchanged was 30 mL/kg,
which is much less than the previously mentioned studies.
The number of sessions of PE was also comparatively less
(range, 2e5). Apheresis was well tolerated by our cohort of
recipients and no major adverse events (AEs) were
observed. There were no bleeding complications. The
replacement ﬂuid used was FFP and Ringer’s lactate.
Albumin was not used as the replacement ﬂuid, which made
the regimen more cost effective. No prophylactic post-
transplantation sessions of apheresis were done, unlike the
previously mentioned studies, unless there was a biopsy-
proven ABMR.
Few successful transplantations have been done in kid-
ney transplant recipients (KTRs) with high initial isoag-
glutinin titers (1:1024) [10,19,32e34,40]. We have come
across only a few case reports with successfultransplantations with a titer of 1:2048 [43]. We have suc-
cessfully performed transplantations in patients with high
isoagglutinin titers, 2 with a baseline titer of 1:1024 and 1
with 1:2048, and achieved excellent graft function. There
was no rebound of isoagglutinins and no post-
transplantation apheresis was required. Only IgG titers
have been mentioned in our study because IgG is more
speciﬁc for ABMR than IgM [44].
The dose of rituximab used in most centers is 375 mg/m2
of body surface area given 4 weeks prior to transplantation
[25,28,34,35,37e39]. We used a comparatively lower dose
(200 mg/body) of rituximab. A single infusion was given 2
weeks prior to transplantation with excellent graft and pa-
tient survival rates without any increase of infectious com-
plications. Only a few preconditioning protocols have used
reduced doses of rituximab. Shirakawa et al [25] decreased
the dose to 200 mg/body in the later phase after using 500
mg/body initially. The graft and patient survival rates were
similar with both dosages, suggesting that rituximab in the
dose of 200 mg is sufﬁcient for ABOiKT. Another
comparative study has suggested that the lower doses of
rituximab might be sufﬁcient for ABOiKT. Different doses
of rituximab (100 mg/200 mg/1000 mg) were given to 3
subgroups of ABOiKTRs and 1 year post-transplantation
the graft survival rate was 100% [26].
In the present study, we have given a 10e25 g dose of
IVIG, which is lower than most of the other protocols. In a
few other studies, a single dose of 0.5 g/kg IVIG was given
pretransplantation [21,22,38].
All these measures led to major economic savings as well
as better results because there were no thrombotic episodes
in our cohort. We achieved excellent graft function at a
median follow-up duration of 370 days with a serum creat-
inine level of 1.20 mg%. This is similar to other centers
ABO-INCOMPATIBLE LIVING DONOR RENAL TRANSPLANTS 2627across the globe that have reported the following serum
creatinine levels: 1.54 mg% by Wilpert et al [22] at 39
months, 1.39 þ 0.51 mg% by Fuchinoue et al [26] at 1 year,
1.3 mg% by Montgomery et al [10] at 1 year, 1.2 þ 0.2 mg%
by Lipshutz et al [40] at 1 year, 1.5 mg% at 1 year by van
Agteren et al [38], 1.44 mg% at 1 year Schousboe et al [21],
and 1.5 mg% at 13 months by Morath et al [34].
The death-censored graft survival rate and the patient
survival rate were 97.78% in the cohort, which is compa-
rable with other centers worldwide. The 1-year death-
censored graft survival rate was 96%, and the patient
survival rate was 96% in 50 ABOiKT using TPE, rituximab,
and IVIG [38]. Montgomery et al, in their study have found
1-year graft survival rate and patient survival rate of 98.3%
and 96.3%, respectively [10]. Fuchinoue et al [26] and Oettl
et al [19] have described a 100% graft survival rate at 1 year.
In another study, Wilpert et al [22] have reported a death-
censored graft survival rate of 100% and patient survival
rate of 98%. Lipshutz et al [40] reported a death-censored
graft survival rate of 94.4% and patient survival rate of
100%. Schousboe et al [21] reported a 1-year graft survival
rate of 97.2%. Morath et al [34] reported an 18-month graft
survival rate of 100% and a patient survival rate of 94.4%.
Barnett et al [45] had a death-censored allograft survival
rate of 98.4% and a patient survival rate of 94.5% at 1 year
of follow-up.
In Japan, more than 2000 such transplantations have
been done since 1989. A registry analysis has shown an
overall 1-year patient survival rate of 97% and a graft sur-
vival rate of 93%. Presently, ABOi renal transplantations
account for w30% of all living renal transplantations per-
formed in Japan [31,46].
In conclusion, we have come a long way since the earliest
attempts were made for crossing the blood group barrier
and with a simple preconditioning protocol. We have been
able to successfully achieve excellent graft function even in
recipients with high isoagglutinin titers. Our precondition-
ing protocol comprises conventional therapeutic apheresis
with a low volume of PE rather than other expensive mo-
dalities like DFPP or antigen-speciﬁc IA. The replacement
solution used during PE was FFP instead of albumin, which
is cheaper as well as replete with all the coagulation factors.
Both rituximab and IVIG were given in relatively lower
doses reducing the expenses as well as AEs. Isoagglutinin
titers were measured by column agglutination, which does
not require elaborate infrastructure. We found this regimen
of preconditioning effective as well as ﬁnancially viable for
ABOiKTs to ﬁnd widespread application in the modern era
of renal transplantation.
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